The Growth Hormone Stack: CJC-1295, Ipamorelin and MK-677

Who this is for

You are somewhere in your late thirties or forties. Sleep is not what it was, a heavy session costs you an extra day, and the body composition you had at thirty does not come back the way it used to.

Somebody has offered a fix. A clinic, a coach, a friend who runs it, a website with a clean logo. The offer is almost always CJC-1295 paired with ipamorelin, with MK-677 either instead or alongside.

This is not a protocol. It is what the human record actually contains.

What people actually run

Reporting what circulates, not recommending it.

The pairing is CJC-1295 and ipamorelin, injected under the skin, in cycles of roughly 8 to 16 weeks. The conventions documented in the peer reviewed literature are 1 to 2 mg per week of the version with DAC, or 100 to 200 mcg per injection once or twice daily for the version without it, alongside 200 to 300 mcg of ipamorelin per injection, one to three times a day. MK-677 is swallowed rather than injected, at 10 to 25 mg once daily.

The reason offered is that the two act on different receptors, one on the growth hormone releasing hormone receptor and one on the ghrelin receptor, so together they should produce more growth hormone than either alone. The receptors really are different. That mechanism is the entire basis, and no study sits underneath it.

What each one is actually built on

CJC-1295. It exists in two forms and almost nobody selling it explains the difference. The original carries a chemical clip that fastens it to albumin, the most abundant protein in blood, which is why it lasts about a week and why the human trials found anything at all. The version usually sold for daily injection has that clip removed, and a 2026 review graded it in the bottom evidence tier with the note "no peer-reviewed human studies." The full breakdown of the two versions is here.

Ipamorelin. Two registered human trials, both in patients whose bowels would not restart after surgery. The published one missed its endpoint, and its authors concluded there were no significant differences between ipamorelin and placebo. The larger one, 320 patients across 45 hospitals at up to twice the dose, finished in May 2014 and has never reported anything, anywhere. Including what the famous selectivity claim was measured in, which was pigs.

MK-677. It was never abandoned. The molecule Merck shelved is now Lumos Pharma's LUM-201, in a Phase 3 recruiting children since 20 May 2026 at 1.6 mg per kilogram per day. Adults take a flat 25 mg, traced to a 1996 study in 32 people aged 64 to 81 where it won by being the largest of three arms, and never re-derived for anybody since. Its longest trial ran two years in 65 adults, and the authors wrote that the increased fat free mass did not result in changes in strength or function. The whole file is here.

Nobody has studied the combination

This tends to land hardest, because the stack is sold as a system.

A search of the published literature for CJC-1295 and ipamorelin together returns nine records. Eight are narrative reviews published in 2026. The ninth is a 2013 method paper on doping control in horses. No original study in there administered both and measured an outcome, in humans or in any animal, and ClinicalTrials.gov has no registered trial of the pairing.

The 2026 review that grades this evidence says so itself. It describes the version without the clip as often used with ipamorelin to increase pulsatile growth hormone release, then notes that controlled evidence for synergy, or for body composition outcomes, remains limited.

The synergy story is not a finding that got overstated. It is a diagram of two receptors nobody has tested as a pair.

Why the doses running lower is not the reassurance it sounds like

In most of this field the community number sits above what the research supports. Here the two injectables run underneath it. Per day, the ipamorelin convention is 5 to 21 times smaller than what the published trial gave, and 1 to 2 mg a week of CJC-1295 with the clip is roughly a quarter to a half of one dose from the pivotal trial. For the version without the clip there is nothing to compare against, because the studied range does not exist.

A dose below the studied range is still a dose no trial administered. Nobody has measured what 1 mg a week does. Under the lowest point anybody measured is not a safe zone, it is the far side of the record in the more comfortable direction. Smaller is a statement about exposure, not an argument that anything happens.

And the comparison is not clean arithmetic. Every published human dose of ipamorelin went into a vein, in hospital. The convention goes under the skin at home, and no human pharmacokinetic data for that route has ever been published. The smaller number is smaller in a unit nobody has converted. It is a price quoted in a currency with no published exchange rate, and knowing the figure is lower does not tell you what you paid.

Duration runs the other way, which is easy to miss. The trials ran 28 and 49 days against a convention of 8 to 16 week cycles, and there is no published human safety data past 49 days for the clipped version and none at all for the other one.

The honest read

Think of it as three references for the same job candidate.

The first is glowing, and it describes somebody else. The results everyone quotes belong to the molecule with the clip attached, and the clip is the defining feature rather than an upgrade.

The second was written, sealed and never sent. Somebody looked at 320 people for three years and the answer has sat somewhere private since 2014.

The third arrived in full, the longest and most detailed of the three, and what it says is that after two years the candidate was no stronger.

Now set that against what you were sold. Body composition and strength: no published human trial of CJC-1295 or ipamorelin measured either, and the one compound that did, over two years, found about a kilogram of fat free mass and no change in strength or function. Sleep: the entire human sleep laboratory record for MK-677 is one 1997 study in 14 subjects, whose older group of six had no placebo arm. Recovery: MK-677 missed its functional endpoints in both hip fracture trials.

MK-677 is the instructive one, because it did not fail to move the biomarker. It raised IGF-1 in every trial, across six populations and three decades, and then each trial measured the thing it actually cared about and came back blank. Ipamorelin has never had IGF-1 reported in a human at all.

This is close to the exact inverse of the GLP-1 compounds, the other thing readers this age get sold. There, the evidence is settled and the argument is entirely about what is in the vial. Here the vial question still applies, and underneath it there is no settled result waiting to be diluted.

None of that means these compounds do nothing. Nobody has shown that either. It means the confident version of this stack is not a summary of evidence.

If you are going to do this anyway

This is the part I care about, because it is where people get hurt, and it has little to do with the molecules.

What is in the vial. For ipamorelin the published finding is not weak product, it is a different molecule. Two independent lab groups testing illicit material found Gly-ipamorelin, an extra amino acid stuck on the front, instead of ipamorelin. Neither was measuring vial contents against labels, so this says nothing about what fraction of vials are affected, and nobody has published what the altered version does in a person. You can check for it if you check the right number: real ipamorelin weighs 711.9 and the altered version sits near 768.9, so what you want on a certificate is m/z 712.4 rather than 769.4.

The CJC-1295 check is simpler. Ask which molecule the certificate names, the form with the clip or the one with nothing published behind it. Their masses differ and the report settles it. On the oral side, of 44 products sold online as SARMs, only 18 held the labelled amount of the labelled compound, and ibutamoren was named among the contaminants found in others.

The standard is the same for all three: identity by mass spectrometry, purity by chromatography, and content, a separate number from purity and the one almost everyone skips. How to read a certificate, walked through on two real ones.

The arithmetic. Reconstitution errors are how people end up a factor of ten off their intended dose using a perfectly good vial, and the syringe markings do not measure what most people assume. The full walkthrough is here.

What would make you stop. The adverse effects worth knowing come from the MK-677 record, the only one of the three with long human exposure behind it.

Glucose first. It rose significantly in the 1996 study, and in the two year trial fasting glucose rose about 0.3 mmol/L, roughly 5 mg/dL, while insulin sensitivity declined. Two of that trial's own investigators later called it a mild rise in insulin resistance at one year, with a rise in HbA1c they judged unlikely to be clinically significant. That hedge is theirs and it is worth carrying. The trial in obese men is the one to read closely: fasting glucose and insulin were unchanged at eight weeks, while a glucose tolerance test showed impaired glucose homeostasis at both two and eight weeks. A clean fasting panel here is reassurance from a test already shown to under-report the effect.

Then oedema and appetite. The most frequent side effects in the two year trial were increased appetite, which subsided within a few months, transient mild swelling of the lower legs, and muscle pain.

Then heart failure. A trial in 123 elderly hip fracture patients on 25 mg daily stopped early over congestive heart failure, and its authors concluded the safety profile was unfavourable. That much is published. The case breakdown that circulates everywhere is not: the abstract says only that a limited number of patients were involved, the full text is paywalled, and the FDA document that would carry the counts returns a 404. The other hip fracture trial excluded people with existing congestive heart failure, diabetes, cancer or uncontrolled hypertension, so reassurance from it describes a screened group.

All three are also banned at all times in tested sport, under WADA section S2.

My take

With BPC-157 the complaint writes itself: nobody did the work. That does not apply here, which is what makes this stack interesting.

Somebody did the work three times. ConjuChem built a genuinely clever molecule and tested it under placebo control in real people. Novo Nordisk designed ipamorelin and Helsinn ran two controlled trials across more than sixty hospitals. MK-677 went through decades of randomised trials and is in an active Phase 3 right now.

What bothers me is not thin evidence. Thin evidence is ordinary and honest. It is that in every case a real document sits in the background doing the persuading, and none of them says what the sales page implies. A trial that missed. A trial that finished twelve years ago and never reported. A per kilogram rule for children sitting next to a flat number inherited from 32 people in their sixties and seventies in 1996.

If this stack does something, it will still do it after somebody tests the pair. Right now the people finding out are the ones paying for it.

---

If a clinic or a coach sold you CJC-1295 with ipamorelin, the question I would like answered is what they told you the two together do that either one alone does not, and what they cited when you asked. There are nine records for that pairing, and eight of them are reviews written this year.

---

This content is for educational and informational purposes only and is not medical advice. Peptides discussed are research compounds and may not be approved for human use. Nothing here should be used to diagnose, treat, cure, or prevent any disease. Always consult a qualified healthcare professional before starting any peptide, supplement, or protocol. Individual responses vary. Do not self-administer compounds without proper medical supervision.